Gastric Inhibitory Polypeptide Receptor - Pipeline Review, H1 2019

Technology

Summary

Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) pipeline Target constitutes close to 13 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes. The latest report Gastric Inhibitory Polypeptide Receptor Pipeline Review, H1 2019, outlays comprehensive information on the Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Download FREE Sample of this Report @ https://www.grandresearchstore.com/report-sample/gastric-inhibitory-polypeptide-receptor-pipeline-review-h-2019-798

Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) Glucose dependent insulinotropic polypeptide receptor (GIPR) is a transmembrane protein in humans which is encoded by the GIPR gene. GIPR is expressed on pancreatic beta cells which lead to activation and release of insulin. The transcription of this protein is positively controlled by glucose molecules. GIPR is expressed in higher levels when glucose is in higher concentration. The ligand which binds to GIPR is glucose dependent insulinotropic polypeptide (GIP) also known as gastric inhibitory polypeptide. Glucose dependent insulinotropic polypeptide is released from the duodenum and small intestine.

GIP binds to GIPR though hydrophobic interactions and triggering activation of G protein coupled receptors, which in turn causes an enzymatic cascade resulting in the increased secretion of insulin. Endogeonous ligands for the receptor include oleylethanolamide and lysophosphatidylcholine. The cause of type 2 diabetes is due to the inability of GIP to bind properly to GIPR. The molecules developed by companies in Phase III, Phase I, Preclinical and Discovery stages are 1, 3, 5 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 3 molecules, respectively.

The report covers products from therapy areas Metabolic Disorders, Central Nervous System and Gastrointestinal which include indications Obesity, Type 2 Diabetes, Alzheimer’s Disease, Non Alcoholic Steatohepatitis (NASH), Non Alcoholic Fatty Liver Disease (NAFLD), Parkinson’s Disease and Circadian Rhythm Sleep Disorders. Furthermore, this report also reviews key players involved in Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR)
The report reviews Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry specific sources
The report covers pipeline products based on various stages of development ranging from pre registration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved in Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics and enlists all their major and minor projects
The report assesses Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
Identify and understand the targeted therapy areas and indications for Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR)
Identify the use of drugs for target identification and drug repurposing
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) development landscape
Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Get the Complete Report & TOC @ https://www.grandresearchstore.com/life-sciences/gastric-inhibitory-polypeptide-receptor-pipeline-review-h-2019-798

Table of content

List of Tables
List of Figures
Introduction

Global Markets Direct Report Coverage
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) — Overview
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) — Therapeutics Development

Polypeptide Receptor or GIPR) — Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type

Key Que Answered in this report:

What will the Global Gastric Inhibitory Polypeptide Receptor?
What are the key factors driving the Global Gastric Inhibitory Polypeptide Receptor?
What are the key market trends in the Gastric Inhibitory Polypeptide Receptor?
improve pasting the growth of this Gastric Inhibitory Polypeptide Receptor?
What are the challenges to the Gastric Inhibitory Polypeptide Receptor?
What are the market opportunities and threats faced by the Gastric Inhibitory Polypeptide Receptor?
What are the key outcomes of the five forces analysis of the Gastric Inhibitory Polypeptide Receptor?

What is our report offers:

Strategic suggestions and proposals for the beginners to understand
Assessments of the market share from different countries and regions were conducted
Top key market players, market share analysis included.
The market observations such as constraints, drivers, threats, opportunities, investment opportunities, challenges, and recommendations are added.
The competitive landscaping mappings of the ongoing trends are discussed.
Based on the market estimations, the strategic recommendations are made in the business segments

CONTACT US:
276 5th Avenue, New York, NY 10001, United States
International: (+1) 646 781 7170 / +91 8087042414
Email: help@grandresearchstore.com

Submitted 6 years 3 months ago by NewsandPR.